Subclinical Organ Damage in Overweight and Obese Patients: Does Presence of Metabolic Syndrome Matter?

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-10-31

Study Completion Date

2012-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Microalbuminuria and homocysteine levels are shown to be markers for endothelial dysfunction and subclinical organ damage and predictors of cardiovascular risk in several epidemiologic and randomized clinical trials. Carotis intima-media thickness is also found to be elevated in early stages of atherosclerosis. Recent studies have shown correlations between homocysteine, microalbumin levels and carotis intima-media thickness in type 2 diabetics but no data exists for obese or overweight patients who also have metabolic syndrome, in terms of markers of subclinical organ damage. Since obesity is a risk factor for cardiovascular disease and since it is known that patients with metabolic syndrome are at higher risk of cardiovascular events, the investigators wanted to examine whether there is an association between homocysteine, microalbumin levels and carotid intima-media thickness in patients with or without metabolic syndrome, who are either overweight or obese.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Potential Role of Dietary Antioxidant Capacity on Age-Related Macular Degeneration

NCT03326401

Age Related Macular Degeneration

COMPLETED

Natural History, Pathogenesis, and Outcome of Ocular Disorders

NCT02821767

Eye Disease

RECRUITING

CArotenoid in hypoChOlesterolemia

NCT05208879

Primary Intestinal Hypocholesterolemia Abetalipoproteinemia Chylomicron Retention Disease

COMPLETED

The Impact of Systemic Light Chain Amyloidosis on Eyes

NCT06803082

Systemic Light Chain Amyloidosis Ocular Complications

RECRUITING

Natural History of Eye Diseases Related to ABCA4 Mutations

NCT01736293

Retinal Degeneration ABCA4-Related Retinopathies

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metabolic Syndrome Subclinical Organ Damage Overweight Obese

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

With Metabolic Syndrome

No interventions assigned to this group

Without Metabolic Syndrome

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 18-80 years
2. BMI \>= 25
3. Ex or non-smokers (must have quit smoking at least 5 years ago)

Exclusion Criteria

1. NIDDM or IDDDM
2. Nephropathy (GFR \< 60 ml/min), previous history of coronary artery disease or peripheral arterial disease
3. Current smokers
4. Active infection or other acute illness

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes